Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation

ESMO Congress 2022

9 - 13 Sep 2022

Published: 12 Sep 2022

Views: 103

Rating:

Save

Dr Melissa Johnson - Sarah Cannon Research Institute, Nashville, USA

Dr Melissa Johnson presents the primary analysis of the phase 3 CodeBreaK 200 trial comparing sotorasib versus docetaxel in previously treated KRAS G12C-mutated NSCLC.

In this first, randomised phase 3 trial for a KRAS G12C inhibitor, oral sotorasib demonstrated superior PFS and ORR compared to intravenous docetaxel and had a more favourable safety profile.

Related Videos

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

The use of IORT at Universitätsmedizin Mannheim hospital

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany

The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan

Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston...

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecan ( Prof Naoto Ueno - The University of Texas MD Anderson Cancer Center, Houston, USA )

How air pollution may trigger lung cancer in never-smokers

Prof Charles Swanton - Francis Crick Institute, London, England

How air pollution may trigger lung cancer in never-smokers ( Prof Charles Swanton - Francis Crick Institute, London, England )

Tumour-infiltrating lymphocyte treatment for advanced melanoma

Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands

Tumour-infiltrating lymphocyte treatment for advanced melanoma ( Dr John Haanen - Netherlands Cancer Institute, Amsterdam, Netherlands )

Nirogacestat success for desmoid tumours

Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany

Nirogacestat success for desmoid tumours ( Dr Bernd Kasper - Universitätsmedizin Mannheim, Mannheim, Germany )

OncoAlert and ecancer weekly round up for August 8th - 14th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for August 8th - 14th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

More from ecancer